Document:

Exhibit 10.1

    

  

    
    LINE OF CREDIT LETTER AGREEMENT

    

    

    Dated as of July 25, 2022

    

    

    GALECTIN THERAPEUTICS, INC.

    4960 Peachtree Industrial Blvd., Suite 240

    Norcross, Georgia 30071

    

    

    Gentlemen:

    

    

    Richard E. Uihlein, an individual resident of the State of Illinois  (“Uihlein”), hereby
      confirms that he is holding available to Galectin Therapeutics, Inc., a Nevada corporation (the “Company”), subject to the restrictions outlined below, a line of credit to finance the
      Company’s working capital needs in the amount of $60,000,000 (the “Line of Credit”).

    

    

    Each advance made pursuant to the Line of Credit by Uihlein shall be evidenced by an unsecured Promissory Note substantially in the form of Exhibit A attached hereto (each, a “Promissory Note”), executed by a duly authorized officer of the Company, which shall represent the
      Company’s obligation to pay the principal amount of such advance with interest thereon.  Uihlein shall make requested advances promptly after a draw is submitted by the Company. The Line of Credit may be drawn upon through July 31, 2024, through
      draws no more frequently than monthly.  As set forth therein, the Promissory Notes shall bear interest (based upon the principal amount outstanding from time to time) payable on or before January 31, 2026, at the Applicable Federal Rate for short
      term loans published by the Internal Revenue Service as may be in effect at the time of such applicable advance, which interest rate on the date hereof is 2.84%, plus two (2%) percent. Interest on the Promissory Notes will compound monthly and
      accrue. Only with the consent of Uihlein, may the Promissory Notes be prepaid, in whole or in part, at any time without premium or penalty, but with interest on the amount prepaid.

     

    

    The date and amount of any borrowing pursuant to the Line of Credit and each payment of principal in respect thereof shall be (i) reflected by the
      Company on Schedule 1 attached hereto, which Schedule 1 shall be amended by the Company from time to time, without any further
      action by Uihlein , to reflect each new advance pursuant to the Line of Credit.

     

    

    At the election of Uihlein, the principal and accrued interest on a Promissory Note may be converted into the number of shares of the Company’s common
      stock (the “Common Stock”) equal to the amount of principal and accrued interest on such Promissory Note divided by the price equal to the closing price of the Common Stock on the date of
      such Promissory Note, but in no event less than $3.00 per share.

     

    

    
      
        

    

    
    In consideration for making the Line of Credit available, the Company shall issue warrants to Uihlein, exercisable to purchase an aggregate of
      1,700,000 shares of Common Stock (collectively, the “Warrants”) in substantially the form attached hereto as Exhibit B.  Upon
      execution of this Line of Credit Agreement, the Company shall issue Uihlein a Warrant that is exercisable to purchase 500,000 shares of Common Stock at an exercise price of $5.00 per share. With respect to the remaining 1,200,000 shares of Common
      Stock (the “Remaining Warrant Shares”), the Company shall issue Uihlein Warrants that are exercisable to purchase the Remaining Warrant Shares, ratably, at the time of the draws, with exercise prices equal to 150% of the closing price of the Common
      Stock on the date of the Promissory Note evidencing such draw, but in no event more than $10.00 per share nor less than $3.00 per share. For example, if $1,000,000 has been advanced on the Line of Credit in the aggregate, then the Company will issue
      Uihlein a Warrant exercisable to purchase 20,000 shares of Common Stock. The Warrants expire on July 31, 2029.

     

    

    Any shares of Common Stock issued to Uihlein upon (i) conversion of a Promissory Note or (ii) exercise of the Warrant, shall be accompanied by
      registration rights whereby the Company shall agree to register the shares of Common Stock with the Securities and Exchange Commission (the “SEC”) within 180 days of the conversion of a
      Promissory Note or exercise of the Warrant, as the case may be.

     

    

    In the event that the Company on or after July 31, 2022 raises additional capital from at-the-market sales, other financings, exercise of warrants or
      options, from license or similar fees received from pharmaceutical or other companies or from strategic or financial partnerships or ventures (collectively, “Other Funding”) then Uihlein
      may, at his election, within 30 days after the end of each calendar quarter containing Other Funding, reduce the size of the Line of Credit on a dollar for dollar basis determined by the amount of the Other Funding actually received, but in no event
      may Uihlein elect to reduce the size of the Line of Credit below the amount that is then drawn under this Line of Credit Agreement.

     

    

    In connection with this Letter of Credit Agreement, all officers and directors of the Company were requested to enter into a lockup agreement (the “Lockup Agreement”), in substantially the form attached hereto as Exhibit C,  whereby they will each agree not to sell Common Stock
      through January 31, 2023 and will suspend any Rule 10b-5-1 plans that they have until such date.

     

    

    To the extent that NASDAQ requires stockholder approval of this Letter of Credit Agreement and the issuance of Common Stock from any conversion of the
      Promissory Note(s) and/or exercise of the Warrant, the Company shall seek approval from its stockholders at its 2022 annual meeting. Furthermore, Uihlein acknowledges and understands that the issuance of Common Stock resulting from any conversion of
      the Promissory Note and/or the exercise of Warrants shall not exceed 20% of the outstanding shares of the Common Stock as of the date hereof, unless this Letter of Credit Agreement has been approved by the Company’s stockholders at a duly held
      meeting of stockholders.

     

    

    The Company agrees that so long as any Promissory Note is outstanding the Company will not grant a security interest in the material assets of the
      Company to any person or entity.

     

    

    No other document shall evidence the indebtedness of Uihlein which may be created pursuant to the terms of this Line of Credit,
      other than the Promissory Note.

    
      2

      
        

    

    This Line Letter shall be governed by, construed and interpreted in accordance with the laws of the State of Georgia.

    	

          	
            Very truly yours,

          
	

          	

          
	

          	
            /s/ Richard E. Uihlein

          
	

          	
            Richard E. Uihlein

          
	

          	

          
	
            Agreed and Accepted as of

          	

          
	
            July 25, 2022

          	

          
	 	

          
	
            GALECTIN THERAPEUTICS, INC.

          	

          
	

          	

          
	
            By:

          	
            /s/ Joel Lewis

          	

          

    
      	
              Name:

            	
              Joel Lewis

            	

            
	
              Title:

            	
              Chief Executive Officer

            	

            

       

      

    

    
      3

      
        

    

    SCHEDULE 1

    SCHEDULE OF ADVANCES

     

    

    	
            Date

          	
            Lender

          	
            Amount

            of

            Advance

          	
            Unpaid

            Aggregate 

            Principal

            Balance

          	
            Notation

            Made By

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          
	
            __________

          	
            __________

          	
            __________

          	
            __________

          	
            __________

          

     

      

    
      
        

    

    EXHIBIT A

    

    

    FORM OF CONVERTIBLE PROMISSORY NOTE

    

    

    CONVERTIBLE PROMISSORY NOTE

    

    

    	
            $

          	

          	

          	
            Atlanta, Georgia

          
	

          	

          	

          	
            Dated as of ___, 2022

          

    

    

    FOR VALUE RECEIVED, the undersigned, GALECTIN THERAPEUTICS, INC., a Nevada corporation (the “Company”),

      hereby unconditionally promises to pay to the order of Richard E. Uihlein, an individual resident of the State of Illinois (“Lender”), whose office address is 12575 Uline Drive, Pleasant
      Prairie, WI 53158, on January 31, 2026, in lawful money of the United States of America and in immediately available funds, the principal amount of (a) _____________________ DOLLARS ($_______________).  The Company further agrees to pay interest in
      like money at an annual rate of ______% [the Applicable Federal Rate for short term loans as may be in effect on the date of the Promissory Note as published by the Internal Revenue Service plus two (2%) percent] on the unpaid principal amount hereof
      from time to time outstanding, which shall compound monthly and accrue commencing on the date hereof and continuing until paid in full on January 31, 2026 or sooner prepaid.

      

    

    This Promissory Note is made pursuant to that certain Line of Credit Letter Agreement, dated as of July___, 2022, by and between Lender and the
      Company, and the Company and the Lender are entitled to the benefits and obligations thereof.  Only with the consent of Lender, this Promissory Notes may be prepaid, in whole or in part, at any time without premium or penalty, but with interest on
      the amount prepaid..

     

    

    At the election of Lender, the principal and accrued interest on this Promissory Note may be converted into the number of shares of the Company’s
      common stock (the “Common Stock”) equal to the amount of principal and accrued interest on this Promissory Note divided by the price equal to the closing price of the Common Stock on the
      date of this Promissory Note.

     

    

    The Company, for itself and all other persons who now are or who may become liable for the payment of all or any part of the obligations evidenced by
      this Promissory Note, jointly, severally and irrevocably, hereby waives presentment for payment, demand, protest, notice of protest, notice of dishonor and any and all other notices and demands whatsoever.  The Company shall pay all costs and
      expenses of collection, including, without limitation, reasonable attorneys’ fees except to the extent limited or prohibited by law.

     

    

    No act, omission, or other failure on the part of Lender or any holder of this Note to exercise any right, remedy or recourse hereunder with respect
      to the Company, whether before or after the occurrence of a default, shall constitute waiver or release of any such right, remedy, recourse, default by such holder or on behalf of any other holder; such waiver or release to be effected only through a
      written document executed by Lender or such holder and then only to the extent specifically recited therein.  A waiver or release with reference to any one event shall not be construed as continuing, as a bar to, or as a waiver or release of, any
      subsequent right, remedy or recourse as to a subsequent event.

     

    

    
      
        

    

    
    This Promissory Note shall be governed by, construed and interpreted in accordance with the laws of the State of Georgia.

     

    

    	

          	
            GALECTIN THERAPEUTICS, INC.

          
	

          	

          
	

          	
            By:

          	

          	

          

    	

          	
            Name:

          	
            Joel Lewis

          
	

          	
            Title:

          	
            Chief Executive Officer

          

     

    

    
      2

      
        

    

    EXHIBIT B

    

    

    FORM OF WARRANT

    

    

    
      
        

    

    
      NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF SUCH WARRANTS, NOR ANY INTEREST IN OR
        RIGHTS UNDER SAME, HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE LAWS OF ANY STATE, AND NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF SUCH WARRANTS,
        NOR ANY INTEREST IN OR RIGHTS UNDER SAME, MAY BE SOLD OR OTHERWISE TRANSFERRED UNLESS REGISTERED UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE.

      

      

      Warrant No. [ ]

      

      

      GALECTIN THERAPEUTICS, INC.

      COMMON STOCK PURCHASE WARRANT

      

      

      Galectin Therapeutics, Inc., a Nevada corporation (the “Company”), for value received and subject to the terms set forth below hereby grants to
        Richard E. Uihlein, or its registered successors and assigns (the “Holder”), the right to purchase from the Company at any time or from time to time until the date and time permitted under Section 2.1 below, [ ] ([ ]) fully paid and non-assessable
        shares of the Common Stock, at the purchase price of [ ] ($[ ]) per share (the “Exercise Price”). This Warrant is issued pursuant to that certain Line of Credit Letter Agreement, dated as of July __, 2022, by and between the Company and the Holder
        (the “Line of Credit Letter Agreement”).  The Exercise Price and the number and character of such shares of Common Stock purchasable pursuant to the rights granted under this Warrant are subject to adjustment as provided herein.

       

      1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Line of Credit Letter Agreement. As used herein the
        following terms, unless the context otherwise requires, have the following respective meanings:

       

      “Common Stock” means the Company’s
        common stock and stock of any other class of securities into which such securities may hereafter have been reclassified or changed into, including any stock (other than Common Stock) and other securities of the Company or any other Person
        (corporate or other) which the Holder of this Warrant at any time shall be entitled to receive, or shall have received, upon the exercise of this Warrant, in lieu of or in addition to Common Stock, or which at any time shall be issuable or shall
        have been issued in exchange for or in replacement of Common Stock pursuant to Section 3.2 hereof or otherwise.

       

      “Common Stock Equivalents” means any
        securities of the Company or its subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time
        convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

       

      “Issue Date” means July ___, 2022.

       

      “Market Value” means, for any date, the
        price determined by the first of the following clauses that applies:  (a) if the Common Stock is then listed or quoted on a Trading Market (other than the OTC Bulletin Board), the daily volume weighted average price of the Common Stock for such
        date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg Financial L.P. (based on a Trading Day from 9:30 a.m. Eastern Time to 4:00 p.m. Eastern Time); (b) if the Common
        Stock is then listed or quoted on the OTC Bulletin Board, the average of the high and low price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board; or (c) if the Common Stock is not then listed or quoted on
        a Trading Market and if prices for the Common Stock are then reported in the “Pink Sheets” published by the Pink Sheets, LLC (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share
        of the Common Stock so reported.

       

      
        
          

      

      “This Warrant” means, collectively,
        this Warrant and all other stock purchase warrants issued in exchange therefor or replacement thereof.

       

      “Trading Day” means a day on which the
        common Stock is traded on a Trading Market.

       

      “Trading Market” means any of the
        following markets or exchanges on which the common Stock is listed or quoted for trading on the date in question: the Nasdaq Stock Market, the New York Stock Exchange, the OTC Bulletin Board or the “Pink Sheets”.

       

      2. Exercise.

       

      2.1 Exercise Period. The Holder may exercise this Warrant at any time after the Issue Date and before the close of business in Norcross, Georgia
        on July 31, 2029 (the “Exercise Period”), unless earlier terminated pursuant to Section 3.2 herein.

       

      2.2 Exercise Procedure.

       

      (a) This Warrant will be deemed to have been exercised at such time as the Company has received all of the following items (the “Exercise Date”):

       

      (i) a completed Exercise Notice as described in Section 2.4 hereof, executed by the Person exercising all or part of the
        purchase rights represented by this Warrant (the “Purchaser”);

       

      (ii) this Warrant;

       

      (iii) if this Warrant is not registered in the name of the Purchaser, an Assignment or Assignments in the form set forth in
        Exhibit B hereto, evidencing the assignment of this Warrant to the Purchaser together with any documentation required pursuant to Section 8(a) hereof; and

       

      (iv) a check payable to the order of the Company in an amount equal to the product of the Exercise Price multiplied by the
        number of shares of Common Stock being purchased upon such exercise.

       

      (b) As soon as practicable after the exercise of this Warrant in full or in part, and in any event within ten (10) days after the Exercise Date,
        the Company at its expense will cause to be issued in the name of and delivered to the Purchaser, or as the Purchaser (upon payment by the Purchaser of any applicable transfer taxes) may direct, a certificate or certificates for the number of fully
        paid and non-assessable shares of Common Stock to which the Purchaser shall be entitled upon such exercise, together with any other stock or other securities and property (including cash, where applicable) to which the Purchaser is entitled upon
        exercise.

       

      (c) Unless this Warrant has expired or all of the purchase rights represented hereby have been exercised, the Company at its expense will, within
        ten (10) days after the Exercise Date, issue and deliver to or upon the order of the Purchaser a new Warrant or Warrants of like tenor, in the name of the Purchaser or as the Purchaser (upon payment by the Purchaser of any applicable transfer
        taxes) may request, calling in the aggregate on the face or faces thereof for the number of shares of Common Stock remaining issuable under this Warrant.

       

      (d) The Common Stock issuable upon the exercise of this Warrant will be deemed to have been issued to the Purchaser on the Exercise Date, and the
        Purchaser will be deemed for all purposes to have become the record holder of such Common Stock on the Exercise Date.

       

      (e) The issuance of certificates for shares of Common Stock upon exercise of this Warrant will be made without charge to the Holder or the
        Purchaser for any issuance tax in respect thereof or any other cost incurred by the Company in connection with such exercise and the related issuance of shares of Common Stock.

       

      
        
          

      

      (f) The holder represents and warrants that at the time of any exercise of this warrant the holder is an “accredited investor,” as such term is
        defined in Rule 501 promulgated under the Securities Act and acknowledges and agrees that the Company may, in its sole discretion, (i) require, as a condition to the exercise of this Warrant, that the holder provide such written evidence that such
        holder is an accredited investor as the time of exercise, and (ii) decline to issue the shares of Common Stock issuable upon such exercise if the Company is not satisfied that this warrant may be exercised by the holder pursuant to a valid
        registration exemption from the Securities Act and any applicable state securities law.

       

      2.3 Acknowledgement of Continuing Obligations. The Company will, at the time of the exercise of this Warrant, upon the request of the Purchaser,
        acknowledge in writing its continuing obligation to afford to the Purchaser any rights to which the Purchaser shall continue to be entitled after such exercise in accordance with the provisions of this Warrant, provided that if the Purchaser shall
        fail to make any such request, such failure shall not affect the continuing obligation of the Company to afford to the Purchaser any such rights.

       

      2.4 Exercise Notice. The Exercise Notice will be substantially in the form set forth in Exhibit A hereto, except that if the shares of Common
        Stock issuable upon exercise of this Warrant are not to be issued in the name of the Purchaser, the Exercise Notice will also state the name of the Person to whom the certificates for the shares of Common Stock are to be issued, and if the number
        of shares of Common Stock to be issued does not include all the shares of Common Stock issuable hereunder, it will also state the name of the Person to whom a new Warrant for the unexercised portion of the rights hereunder is to be delivered.

       

      2.5 Fractional Shares. If a fractional share of Common Stock would, but for the provisions of Section 2.1 hereof, be issuable upon exercise of the
        rights represented by this Warrant, the Company will, within ten (10) days after the Exercise Date, deliver to the Purchaser a check payable to the Purchaser in lieu of such fractional share, in an amount equal to the Market Value of such
        fractional share as of the close of business on the Exercise Date.

       

      3. Adjustments.

       

      3.1 Adjustments for Stock Splits, Etc. If the Company shall at any time after the Issue Date subdivide its outstanding Common Stock, by split-up
        or otherwise, or combine its outstanding Common Stock, or issue additional shares of its capital stock in payment of a stock dividend in respect of its Common Stock, the number of shares issuable on the exercise of the unexercised portion of this
        Warrant shall forthwith be proportionately increased in the case of a subdivision or stock dividend, or proportionately decreased in the case of a combination, and the Exercise Price then applicable to shares covered by the unexercised portion of
        this Warrant shall forthwith be proportionately decreased in the case of a subdivision or stock dividend, or proportionately increased in the case of combination.

       

      3.2 Adjustment for Reclassification, Reorganization, Etc. In case of any reclassification, capital reorganization, or change of the outstanding
        Common Stock (other than as a result of a subdivision, combination or stock dividend), or in the case of any consolidation of the Company with, or merger of the Company into, another Person (other than a consolidation or merger in which the Company
        is the continuing corporation and which does not result in any reclassification or change of the outstanding Common Stock of the Company), or in case of any sale or conveyance to one or more Persons of the property of the Company as an entirety or
        substantially as an entirety at any time prior to the expiration of this Warrant, then, as a condition of such reclassification, reorganization, change, consolidation, merger, sale or conveyance, lawful provision shall be made, and duly executed
        documents evidencing the same from the Company or its successor shall be delivered to the Holder of this Warrant, so that the Holder of this Warrant shall have the right at any time prior to the expiration of this Warrant to purchase, at a total
        price not to exceed that payable upon the exercise of the unexercised portion of this Warrant, the kind and amount of shares of stock and other securities and property receivable upon such reclassification, reorganization, change, consolidation,
        merger, sale or conveyance by a holder of the number of shares of Common Stock of the Company as to which this Warrant was exercisable immediately prior to such reclassification, reorganization, change, consolidation, merger, sale or conveyance,
        and in any such case appropriate provision shall be made with respect to the rights and interests of the Holder of this Warrant to the end that the provisions hereof (including, without limitation, provisions for the adjustment of the Exercise
        Price and of the number of shares purchasable upon exercise of this Warrant) shall thereafter be applicable in relation to any shares of stock, and other securities and property, thereafter deliverable upon exercise hereof. If, as a consequence of
        any such transaction, solely cash, and no securities or other property of any kind, is deliverable upon exercise of this Warrant, then, in such event, the Company may terminate this Warrant by giving the Holder hereof written notice thereof. Such
        notice shall specify the date (at least thirty (30) days subsequent to the date on which notice is given) on which, at 3:00 P.M., Norcross, Georgia time, this Warrant shall terminate. Notwithstanding any such notice, this Warrant shall remain
        exercisable, and otherwise in full force and effect, until such time of termination.

       

      
        
          

      

      3.3 Certificate of Adjustment. Whenever the Exercise Price or the number of shares issuable hereunder is adjusted, as herein provided, the Company
        shall promptly deliver to the registered Holder of this Warrant a certificate of the Treasurer of the Company, which certificate shall state (i) the Exercise Price and the number of shares of Common Stock issuable hereunder after such adjustment,
        (ii) the facts requiring such adjustment, and (iii) the method of calculation for such adjustment and increase or decrease.

       

      3.4 Small Adjustments. No adjustment in the Exercise
        Price shall be required unless such adjustment would require an increase or decrease in the Exercise Price of at least one percent; provided, however, that any adjustments which by reason of this Section 3.4 are not required to be made immediately
        shall be carried forward and taken into account at the time of exercise of this Warrant or any subsequent adjustment in the Exercise Price which, singly or in combination with any adjustment carried forward, is required to be made under Sections
        3.1 or 3.2.

       

      4. Reservation of Stock, etc., Issuable on Exercise of Warrant. The Company
        will at all times reserve and keep available, solely for issuance and delivery upon the exercise of this Warrant, all shares of Common Stock from time to time issuable upon the exercise of this Warrant.

       

      5. Disposition of This Warrant, Common Stock, Etc.

       

      (a) The Holder of this Warrant and any transferee hereof or of the Common Stock with respect to which this Warrant may be exercisable, by their
        acceptance hereof, hereby understand and agree that this Warrant and the Common Stock with respect to which this Warrant may be exercisable have not been registered under the Securities Act, and may not be sold, pledged, hypothecated, donated, or
        otherwise transferred (whether or not for consideration) without an effective registration statement under the Act or an opinion of counsel satisfactory to the Company and/or submission to the Company of such other evidence as may be satisfactory
        to counsel to the Company, in each such case, to the effect that any such transfer shall not be in violation of the Act. It shall be a condition to the transfer of this Warrant that any transferee thereof deliver to the Company its written
        agreement to accept and be bound by all of the terms and conditions of this Warrant.

       

      (b) Except to the extent the resale of the shares of Common Stock issuable upon exercise hereof are registered for resale, or may be sold to the
        public pursuant to Rule 144(b)(1) under the Securities Act, the certificates of the Company that will evidence the shares of Common Stock with respect to which this Warrant may be exercisable will be imprinted with a conspicuous legend in
        substantially the following form:

       

      “THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT BE
        SOLD, PLEDGED, HYPOTHECATED, DONATED OR OTHERWISE TRANSFERRED (WHETHER OR NOT FOR CONSIDERATION) BY THE HOLDER WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND/OR SUBMISSION TO THE
        COMPANY OF SUCH OTHER EVIDENCE AS MAY BE SATISFACTORY TO COUNSEL TO THE COMPANY, IN EACH SUCH CASE, TO THE EFFECT THAT ANY SUCH TRANSFER SHALL NOT BE IN VIOLATION OF THE ACT.”

       

      The Company agrees to prepare and file with the Securities Exchange Commission within 180 days from the date of issuance of any shares of Common
        Stock upon exercise  of this Warrant.

       

      6. Rights and Obligations of Warrant Holder. The Holder of this Warrant
        shall not, by virtue hereof, be entitled to any voting rights or other rights as a stockholder of the Company. No provision of this Warrant, in the absence of affirmative actions by the Holder to purchase Common Stock of the Company by exercising
        this Warrant, and no enumeration in this Warrant of the rights or privileges of the Holder, will give rise to any liability of such Holder for the Exercise Price of Common Stock acquirable by exercise hereof or as a stockholder of the Company.

       

      
        
          

      

      7. Transfer of Warrants. Subject to compliance with the restrictions on
        transfer applicable to this Warrant referred to in Section 5 hereof, this Warrant and all rights hereunder are transferable, in whole or in part to other Lenders pursuant to the Line of Credit Letter Agreement, without charge to the registered
        Holder, upon surrender of this Warrant with a properly executed Assignment (in substantially the form attached hereto as Exhibit B), to the Company, and the Company at its expense will issue and deliver to or upon the order of the Holder hereof a
        new Warrant or Warrants in such denomination or denominations as may be requested, but otherwise of like tenor, in the name of the Holder or as the Holder (upon payment of any applicable transfer taxes) may direct.

       

      8. Replacement of Warrants. Upon receipt of evidence reasonably satisfactory
        to the Company of the loss, theft, destruction or mutilation of any Warrant and, in the case of any such loss, theft or destruction, upon delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case
        of any such mutilation, upon surrender and cancellation of such Warrant, the Company at its expense will execute and deliver, in lieu thereof, a new Warrant of like tenor.

       

      9. Company Records. Until this Warrant is transferred on the books of the
        Company, the Company may treat the registered Holder hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary.

       

      10.  Miscellaneous.

       

      10.1 Notices. All notices and other communications from the Company to the Holder of this Warrant shall be mailed by first class mail, postage prepaid, to such address
        as may have been furnished to the Company in writing by such Holder, or, until an address is so furnished, to and at the address of the last Holder of this Warrant who has so furnished an address to the Company. All communications from the Holder
        of this Warrant to the Company shall be mailed by first class mail, postage prepaid, to Galectin Therapeutics, Inc., 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA 30071, Attn: Chief Financial Officer, or such other address as may
        have been furnished to the Holder in writing by the Company.

      

      

      10.2 Amendment and Waiver. Except as otherwise provided herein, this Warrant and any term hereof may be amended, waived, discharged or terminated only by an instrument
        in writing signed by the party against which enforcement of such amendment, waiver, discharge or termination is sought.

       

      10.3 Governing Law; Descriptive Headings. This Warrant shall be construed and enforced in accordance with and governed by the laws of the State of Nevada. The headings
        in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof.

       

      

      

      [SIGNATURE ON FOLLOWING PAGE]

      
        
          

      

      Dated:   July ___,  2022.

       

      

      

      

      	 	 	 	 
	 	
              GALECTIN THERAPEUTICS, INC.

            
	 	 	 
	 	
              By:

            	 	 
	 	
              Name:

            	 	
              Joel Lewis

            
	 	
              Title:

            	 	
              CEO

            

      

      

      
        
          

      

      EXHIBIT A

      

      

      EXERCISE NOTICE

      

      

      [To be signed only upon exercise of Warrant]

      

      

      	 	 	 
	
              To:

            	 	
              Date:

            

      

      

      The undersigned, the Holder of the within Warrant, pursuant to the provisions set forth in the within Warrant, hereby irrevocably elects to exercise
        the purchase rights represented by such Warrant for, and agrees to subscribe for and purchase thereunder, ___________ shares of the Common Stock covered by such Warrant and herewith makes payment of $ _____________ therefor, and requests that the
        certificates for such shares be issued in the name of, and delivered to, ___________________, whose address is: ________________________________.  If said number of shares is less than all the shares covered by such Warrant, a new Warrant shall be
        registered in the name of the undersigned and delivered to the address stated below.

       

      

      	 	 	 	 
	 	
              Signature

            	 	 
	 	 	 
	 	 	 	
              (Signature must conform in all respects to name of Holder as specified on the face of the Warrant or on the form of Assignment attached as Exhibit B thereto.)

            
	 	 	 
	 	
              Address

            	 	 
	 	 	 
	 	 	 	 
	 	 
	 	
              [Signature Guarantee]

            

      
        
          

      

      EXHIBIT B

      

      

      ASSIGNMENT

      

      

      [To be signed only upon transfer of Warrant]

      

      

      For value received, the undersigned hereby sells, assigns and transfers all of the rights of the undersigned under the within Warrant with respect to
        the number of shares of the Common Stock covered thereby set forth below, unto:

      

      

      	 	 	 	 
	
              Name of Assignee

            	 	
              Address

            	 
	
               

               

               

               

              No of Shares:  Warrants _____________________

              

            	 	 	 

       

      

       

      

      	 	 	 	 	 	 
	
              Dated:          

            	  

            	 	
              Signature

            	 	 
	 	 	 
	 	 	 	 	 	
              (Signature must conform in all respects to name of Holder as specified on the face of the Warrant.)

            
	 	 	 
	 	 	 	
              Address

            	 	 
	 	 	 
	 	 	 	 	 	 
	 	 
	 	 	 	 

      

      

    

    
      
        

    

    EXHIBIT C

    

    

    FORM OF LOCKUP AGREEMENT

     

    

    
      
        

    

    
    
      Lock-up Agreement

      

      

      

      

      July __, 2022

      

      

      

      

      

      

      Galectin Therapeutics, Inc.

      4960 Peachtree Industrial Blvd., Ste. 240

      Norcross, Georgia 30071

      

      

      

      

      Re:     Galectin Therapeutics, Inc. (the “Company”) -
            Restriction on Stock Sales Pursuant to Line of Credit Agreement

      

      

      Dear Sirs/Madam:

      

      

      This letter agreement is delivered to you pursuant to the Line of Credit Agreement (the “Credit Agreement”) to be entered into by the
        Company and Richard Uihlein (the “Lender”).

      

      

      Therefore, as an inducement to the Lender to execute the Credit Agreement, the undersigned hereby acknowledges and agrees that the
        undersigned, the undersigned’s family members and the undersigned’s  affiliates (including any entities managed by or funds affiliated with the undersigned) (collectively referred to as the “Lock-up Parties”) will not (i) offer, sell, contract to
        sell, pledge, assign, encumber, grant any option to purchase or otherwise dispose of (collectively, a “Disposition”) any common stock, options, warrants of other securities of the Company (the “Company Securities”), or any securities convertible
        into or exercisable or exchangeable for, or any rights to purchase or otherwise acquire, any Company Securities held by the Lock-Up Parties after the date hereof, or that may be deemed to be beneficially owned by the Lock-Up Parties (collectively,
        the “Lock-Up Shares”), pursuant to the Rules and Regulations promulgated under the Securities Act of 1933, as amended (the “Act”), and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for a period commencing on the date hereof
        and ending on January 31, 2023 (the “Lock-Up Period”), without the prior written consent of Lender or (ii) exercise or seek to exercise or effectuate in any manner any rights of any nature that the Lockup-Parties has or may have hereafter to
        require the Company to register under the Act the undersigned’s sale, transfer or other disposition of any of the Lock-Up Shares or other securities of the Company held by the Lockup Parties, or to otherwise participate as a selling securityholder
        in any manner in any registration effected by the Company under the Act, including under a registration statement, during the Lock-Up Period. The Lockup Parties agrees that during the Lock-Up Period, the Lockup Parties will not implement a trading
        plan pursuant to Rule 10b-5 of the Exchange Act (“10b-5 Plan”), for the transfer or sale of Company Securities during the Lock-Up Period, and further agreed to suspend any 10b-5 Plan that the undersigned currently has in place. The foregoing
        restrictions are expressly agreed to preclude the Lock-Up Parties from engaging in any hedging, collar (whether or not for any consideration) or other transaction that is designed to or reasonably expected to lead or result in a Disposition of
        Lock-Up Shares during the Lock-Up Period, even if such Lock-Up Shares would be disposed of by someone other than such holder. Such prohibited hedging or other transactions would include any short sale or any purchase, sale or grant of any right
        (including any put or call option or reversal or cancellation thereof) with respect to any Lock-Up Shares or with respect to any security (other than a broad-based market basket or index) that includes, relates to or derives any significant part of
        its value from Lock-Up Shares.

      

      

      
        1

        
          

      

      Notwithstanding the agreement not to make any Disposition during the Lock-Up Period, you have agreed that the foregoing restrictions shall
        not apply to:

      

      

      	

            	(1)	
              Company Securities to be transferred as a gift or gifts, by will or intestacy or to any trust for the direct or indirect benefit of the undersigned or the immediate family of the
                undersigned (provided that any donee or transferee thereof agrees in writing to be bound by the terms hereof);

            

      	

            	(2)	
              the distribution of Company Securities to partners, members, stockholders, or other equity holders of entities controlled by the undersigned; or

            

      	

            	(3)	
              transfers of Company Securities for the primary purpose of satisfying any tax or other governmental withholding obligation with respect to Company Securities issued upon the exercise of
                an option or warrant or the conversion of a security.

            

      

      

      In furtherance of the foregoing, the Company and its transfer agent and registrar are hereby authorized to decline to make any transfer of
        Lock-Up Shares if such transfer would constitute a violation or breach of this letter agreement. This letter agreement shall be binding on the Lock-Up Parties and the respective successors, heirs, personal representatives and assigns of the Lock-Up
        Parties. Capitalized terms used but not defined herein have the respective meanings assigned to such terms in the Credit Agreement.

      

      

      	 	
              Very truly yours,

            
	 	 
	 	 
	 	 
	 	 
	 	
              Name:

            

      

      

    

     

    

  

   
  2Exhibit 10.2

    

  

    
    FORM OF CONVERTIBLE PROMISSORY NOTE

    

    

    CONVERTIBLE PROMISSORY NOTE

     

    

    	
            $

          	 	

          	
            Atlanta, Georgia

          
	

          	

          	

          	
            Dated as of ___, 2022

          

    

    

    FOR VALUE RECEIVED, the undersigned, GALECTIN THERAPEUTICS, INC., a Nevada corporation (the “Company”),

      hereby unconditionally promises to pay to the order of Richard E. Uihlein, an individual resident of the State of Illinois (“Lender”), whose office address is 12575 Uline Drive, Pleasant
      Prairie, WI 53158, on January 31, 2026, in lawful money of the United States of America and in immediately available funds, the principal amount of (a) _____________________ DOLLARS ($_______________).  The Company further agrees to pay interest in
      like money at an annual rate of ______% [the Applicable Federal Rate for short term loans as may be in effect on the date of the Promissory Note as published by the Internal Revenue Service plus two (2%) percent] on the unpaid principal amount hereof
      from time to time outstanding, which shall compound monthly and accrue commencing on the date hereof and continuing until paid in full on January 31, 2026 or sooner prepaid.

     

    

    This Promissory Note is made pursuant to that certain Line of Credit Letter Agreement, dated as of July___, 2022, by and between Lender and the
      Company, and the Company and the Lender are entitled to the benefits and obligations thereof.  Only with the consent of Lender, this Promissory Notes may be prepaid, in whole or in part, at any time without premium or penalty, but with interest on
      the amount prepaid..

     

    

    At the election of Lender, the principal and accrued interest on this Promissory Note may be converted into the number of shares of the Company’s
      common stock (the “Common Stock”) equal to the amount of principal and accrued interest on this Promissory Note divided by the price equal to the closing price of the Common Stock on the
      date of this Promissory Note.

     

    

    The Company, for itself and all other persons who now are or who may become liable for the payment of all or any part of the obligations evidenced by
      this Promissory Note, jointly, severally and irrevocably, hereby waives presentment for payment, demand, protest, notice of protest, notice of dishonor and any and all other notices and demands whatsoever.  The Company shall pay all costs and
      expenses of collection, including, without limitation, reasonable attorneys’ fees except to the extent limited or prohibited by law.

     

    

    No act, omission, or other failure on the part of Lender or any holder of this Note to exercise any right, remedy or recourse hereunder with respect
      to the Company, whether before or after the occurrence of a default, shall constitute waiver or release of any such right, remedy, recourse, default by such holder or on behalf of any other holder; such waiver or release to be effected only through a
      written document executed by Lender or such holder and then only to the extent specifically recited therein.  A waiver or release with reference to any one event shall not be construed as continuing, as a bar to, or as a waiver or release of, any
      subsequent right, remedy or recourse as to a subsequent event.

     

    

    
      
        

    

    This Promissory Note shall be governed by, construed and interpreted in accordance with the laws of the State of Georgia.

     

    

    	

          	

          	
            GALECTIN THERAPEUTICS, INC.

          
	

          	

          	

          	

          
	

          	

          	
            By:

          	

          	

          

    	

          	

          	
            Name:

          	
            Joel Lewis

          	

          
	

          	

          	

          	

          	

          
	
            Title:

          	
            Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]